trial · primary record
BL-M08D1
Melanoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2028-12 |
| Primary endpoint | Recommended Phase II Dose (RP2D) |
| Registry ID | NCT07841925 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:31:45.093Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07841925
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.